Mount Sinai scientists create AI-powered tool to improve cancer tissue analysis

FOR IMMEDIATE RELEASE

Contact:   Diego Ortiz Quintero
Mount Sinai Press Office
201-572-5703
Diego.ortizquintero@mountsinai.org

Mount Sinai Scientists Create AI-Powered Tool
to Improve Cancer Tissue Analysis  
MARQO delivers faster, fully integrated whole-slide image processing across multiple staining technologies

NEW YORK, (August 25, 2025) – Scientists at the Icahn School of Medicine at Mount Sinai have developed a powerful new computational tool that could transform how cancer tissues are analyzed and help pave the way for more personalized treatments. The study, published in Nature Biomedical Engineering, introduces MARQO, a next-generation image analysis process that extracts detailed cellular and spatial information from tumor tissue slides with unprecedented accuracy and scalability.

Developed by a team led by Sacha Gnjatic, PhD, Professor of Immunology and Immunotherapy at the Icahn School of Medicine, MARQO streamlines the complex task of analyzing immunohistochemistry (IHC) and immunofluorescence (IF) images, which are produced via staining methods commonly used to detect immune cells and other biomarkers in cancerous tissues.

When someone has cancer, pathologists inspect stained tissue sections under the microscope to see which cells are present and how they are arranged. Doing this by hand is labor‑intensive and usually limited to small areas of the sample.

MARQO tackles this challenge in three key ways: First, while other tools can process entire images, they often require users to chop slides into patches or rely on costly computing clusters. MARQO keeps slides intact and finishes the job in minutes rather than hours, even on standard graphics processing units. Second, MARQO works with a range of common IHC and IF staining technologies, making study‑to‑study comparisons easier and boosting reproducibility. Third, MARQO automatically flags likely positive cells and assigns coordinates and marker intensities, then hands off the final validation to the pathologist, keeping human expertise at the center of the workflow.

“We designed MARQO to fill a major gap in the field: turning complex whole‑slide images into usable, structured data quickly and consistently,” said Dr. Gnjatic. “By automating the heavy lifting, we let experts focus on interpretation and discovery.”

While MARQO is currently designed for research use and has not been validated for clinical diagnostics, its compatibility with standard clinical staining methods could enable future applications in pathology labs.

The research team plans to continue developing MARQO by improving its user interface, adding advanced spatial and neighborhood analysis tools, and expanding its use in high-performance computing environments to support large-scale projects involving millions of digitized tissue slides.

“This platform could accelerate biomarker discovery, improve how we predict which patients will benefit from specific treatments, and ultimately support the development of more precise cancer diagnostics,” said Dr. Gnjatic.

Co-authors include Mark Buckup (now an MD/PhD student at University of California San Diego); Edgar Gonzalez-Kozlova, PhD, Assistant Professor of Immunology and Immunotherapy in the Gnjatic Lab; Igor Figueiredo, Computer Engineer; Pauline Hamon, PhD (now junior faculty in France); and Giorgio Ioannou, Senior Research Assistant and lead on the mIHC imaging platform.

Funding provided by the National Cancer Institute (U24, P01, and U01 grants), with seed funding from the Icahn School of Medicine at Mount Sinai.

###
 

About the Icahn School of Medicine at Mount Sinai 

The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the seven member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to New York City’s large and diverse patient population. 

The Icahn School of Medicine at Mount Sinai offers highly competitive MD, PhD, MD-PhD, and master’s degree programs, with enrollment of more than 1,200 students. It has the largest graduate medical education program in the country, with more than 2,600 clinical residents and fellows training throughout the Health System. Its Graduate School of Biomedical Sciences offers 13 degree-granting programs, conducts innovative basic and translational research, and trains more than 560 postdoctoral research fellows. 

Ranked 11th nationwide in National Institutes of Health (NIH) funding, the Icahn School of Medicine at Mount Sinai is among the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges.  More than 4,500 scientists, educators, and clinicians work within and across dozens of academic departments and multidisciplinary institutes with an emphasis on translational research and therapeutics. Through Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai.

------------------------------------------------------- 

* Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai.